inins each) combined w i t h H-glucose i n f u s i o n t o independently measure hepatic and,peripheral i n s u l i n s e n s i t i v i t y . Children were s t u d i e d b e f o r e and a f t e r 7-19
weeks o f GH treatment (0.05 mg/kg IM qod) which increased growth r a t e from 4.6+0.9 t o 8.95.4 cmlyr (p<0.02). At t h e time o f t h e second Ttudy, 36h a f t e r t h e , l a s t shot, GH l e v e l s had r e t u r n e d t o b a s e l i n e (2.0s.5 vs 1.79.3 ng/ml) w h i l e somatol~iedin C was s t i l l markedly e l e v a t e d (1.29+0.25 vs 0.29+0.06 U/ml , p<0.01). There was no d i f f e r e n c e i n f a s t i n g plasmn glucose (79.7+3.4 vs 75.9+1.8 mg/dl) o r i n s u l i n (7.4L2.0 vs 6.0~1.4 mU/lr, although h a 1 glucose turnover was s l i g h t l y higher (2.48t0.28 vs 2.11+0.27 mg/kg.min, p.cO.05). However, hepatic g l ucoTe productionsuppressed t o the same e x t e n t d u r i n g t h e low dose clamp (71 vs 85%) , and i n s u l i n s t i m u l a t e d glucose uptake d u r i n g t h e h i g h dose clamp a c t u a l l y tended t o be higher a f t e r GH treatment ( 9 . 4 5 . 9 vs 7,9+0.9 mg/kg.min). I n c o n t r a s t , i n t h r e e c h i l d r e n studied 12h a f t e r a GH shot, i n s u l i n s e n s i t i v i t y was decreased. Thus, 36h a f t e r GH, no adverse e f f e c t s on carbohydrate metabolism were d e t e c t a b l e , and some c h i l d r e n were a c t u a l l y more i n s u l i n s e n s i t i v e , p o s s i b l y as a r e s u l t o f i n s u l i n -l i k e e f f e c t s o f somatomedins. hp GHRH-NH2 infusion. Fourteen patients with growth rate (GR) of 3.7+1.1 d y r had a n o d GH response on CHST (12.9 + 4.5 ng/ml) a;;d GHRH (24.6+12.6) but subnod CGH (2.6M.7) ccnpatible with NSGHD. ~ive-patients with GR of 2.8M.6 ayr had a subnod GH respanse on CHSP (2.65.4) and CGH-(1.6M.3) but a n o m l GH respanse to GHRH (11.325.7) ccnpatibie with GHRH deficiency. Ttm patients with a GR of 3.0 d y r had subnomd respcnses on CHSP !2:3), CGH (1.3) and GHRH (1.6) ccnpatible with pituitary GH deflclency. Eight patients with GR of 4.9+1.3 d y r had n o d respanses on all 3 tests. GH deficiency is %inly hypothalamic in origin. The mst c -n form is the NSGHD with a clinical spectnnn frcm a virtually n o d growth rate dam to swere growth stunting. GHRH deficiw is a less c m , but is mre carmvl than a pituitary GH deficiency. This study damnstrates that cdined physiolqic and phamcologic tests of GH reserve can determine the origin of the disorder. Plaslna SnC/IGFl mcentraticn~~ do nat amdate well with &h -. -. ~t y o f~t i v i n p a n t s a n d~r m r w i f h~~ mtesafQidefYdmtptientschnlngGHtherapy. % a i m o f W s s t 4~ was to obtsln m t a t i w i n f~t i c n a h t the excreticm af SmC/IGi!l in 
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subjects. E i l s a r a n e m e r r t s a f -S a C m m 3 y i n c I E e s e c u r~a b a r t
t h e j n t e r p l a y~t M s m * a n d G f r , s e x~a n d~t i c m . expression was diminished a t 1 day-1 month i n 6/7 pts. Most o f these changes were t r a n s i e n t and none was c l i n i c a l l y evident. 
BIOSYNTHETIC METHIONYL-HUMAN GROWTH HORMONE (BMHGH) TREATMENT AFFECTS IMMUNE FUNCTIONS ( I F ) I N GROWTH HORMONE-DEFICIENT CHILD-
- . . - . . -.
REN. Robert Ra a o r t , Bruce Petersen
of P e d i a t r i c s , Newark. NJ; E l i illy & Co., Indianapolis, 1N
We have previously reported transient depression of % B c e l l s , Phytohemagg l u t i n i n (PHA) responsiveness and T Helper/Suppressor c e l l ( T H/S) r a t i o s i n GH-deficient children during treatment (Tx) with p i t u i t a r y derived human growth hormone (PHGH) ( J Pediatr 109:434, 1986). I n v i t r o , incubation of peripheral blood lymphocytes. (PBL) w i t h GH resulted i n decreased % B c e l l s . The PEL of children undergoing GH Tx had increased baseline and GH stimulated p r o l i f e r a t i o n . I n the current study, we evaluated I F during Tx w i t h BMHGH ( k i n
We provide f i r s t evidence t h a t BMHGH treatment does a f f e c t I F i n children. The e f f e c t s of BMHGH on I F appear t o be s i m i l a r t o those o f PHGH. These data f u r t h e r support our concept o f the presence o f a GH-immune network t h a t needs t o be considered when t r e a t i n g c h i l d r e n w i t h human growth hormone.
VASOPRESSIN mRNA IN THE SUPRAOPTIC AND SUPRACHIAS-MATIC NUCLEI: APPEARANCE
